Can the RoPE (Risk of Paradoxical Embolism) score be applied to a 47‑year‑old hypertensive man with an incidentally discovered patent foramen ovale and no prior stroke or transient ischemic attack?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

RoPE Score Application in Incidental PFO Without Prior Stroke

The RoPE (Risk of Paradoxical Embolism) score cannot and should not be applied to your patient because it was specifically designed and validated only for patients who have already experienced a cryptogenic stroke or TIA—not for asymptomatic individuals with incidentally discovered PFOs. 1, 2

Why the RoPE Score Does Not Apply

The RoPE score is a risk stratification tool that incorporates clinical characteristics (age, history of stroke/TIA, diabetes, hypertension, smoking, cortical infarct on imaging) to predict the likelihood that an already-occurred embolic stroke was caused by a PFO, not to predict future stroke risk in asymptomatic PFO patients. 2

Key Limitations in Your Patient:

  • No qualifying event: The RoPE score requires a cryptogenic stroke or TIA as the index event—your patient has neither 1
  • Wrong population: The score was derived from and validated in stroke patients aged 18-60 years with cryptogenic events, not in asymptomatic individuals with incidental findings 2, 3
  • Misapplication of purpose: The score estimates PFO-stroke causality after the fact, not prospective stroke risk 2

What This Means for Your 47-Year-Old Patient

Current Guideline Recommendations:

No intervention is recommended for asymptomatic, incidentally discovered PFOs. 1

  • The prevalence of PFO in the general population is approximately 25%, and the vast majority remain asymptomatic throughout life 2, 4
  • There are no primary prevention data for patients with asymptomatic PFOs, and given the high prevalence, primary prevention studies may not be feasible 4
  • Current guidelines state there is insufficient evidence to recommend PFO closure in asymptomatic individuals 1

Management Algorithm for Your Patient:

  1. No closure indicated: PFO closure is not beneficial in unselected patients without stroke/TIA 1

  2. Medical management:

    • Continue standard cardiovascular risk factor modification (control hypertension) 1
    • No antiplatelet or anticoagulation therapy is indicated solely for an asymptomatic PFO 1
  3. No routine surveillance: Routine echocardiographic surveillance of asymptomatic PFOs is rated "Rarely Appropriate" 5

  4. Patient education: Counsel that PFO is common in the general population (25%), most remain asymptomatic, and the finding does not require treatment in the absence of a thromboembolic event 1

When RoPE Score WOULD Be Appropriate

The RoPE score should only be calculated if and when this patient experiences a future cryptogenic stroke or TIA. At that point:

  • A RoPE score >8 combined with high-risk PFO anatomical features (large shunt, atrial septal aneurysm) would suggest PFO closure should be considered 1
  • The PASCAL classification system (which incorporates RoPE score plus echocardiographic features) would then guide closure decisions 2, 3
  • Patients with RoPE scores 9-10 have 77% PFO prevalence, suggesting high likelihood of PFO-stroke causality 2

Critical Pitfall to Avoid

Do not use the RoPE score to justify prophylactic PFO closure in asymptomatic patients. This represents a fundamental misunderstanding of the tool's purpose and could expose patients to unnecessary procedural risks (including atrial fibrillation, device-related complications) without proven benefit. 1, 2

The presence of hypertension in your patient is actually a negative predictor in the RoPE score (reduces the likelihood that a stroke would be PFO-related), further emphasizing that this patient does not fit the profile for intervention even if he were to have a stroke. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Patent Foramen Ovale and Stroke.

Current treatment options in cardiovascular medicine, 2003

Guideline

Post-PFO Closure Surveillance Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the management approach for a patient with a patent foramen ovale (PFO) and sinus tachycardia for 24% of the day?
What is the next step in managing an 84-year-old patient with stroke-like symptoms, a patent foramen ovale (PFO) diagnosed by agitated saline imaging on echocardiogram (echo), and Alzheimer's dementia?
At what age does the foramen ovale (FO) typically close in babies?
What is the management plan for a patient with a history of cerebrovascular accident due to embolism, patent foramen ovale, labile hypertension, migraines with aura, and cervical spinal stenosis?
What is the management plan for a 4-year-old child with a tiny patent foramen ovale (PFO) and no symptoms?
Is clopidogrel (Plavix) contraindicated in a patient who is status post MAZE procedure?
How should I interpret an echocardiogram that shows a normal-sized left ventricle with normal wall thickness, preserved systolic function (ejection fraction 55‑60 %), normal diastolic parameters, an enlarged left atrium, trivial mitral regurgitation, and mild tricuspid regurgitation, and what management is recommended?
What is the next best step for rapid glycemic control in a 60‑year‑old woman with type 2 diabetes, fasting hyperglycemia and post‑prandial hyperglycemia, currently taking metformin 1000 mg daily, dapagliflozin 10 mg daily, and human mixtard (30/70) insulin (human mixed insulin 30% regular, 70% NPH) 13 U before breakfast and 13 U before dinner?
What is the appropriate diabetes management for an 88‑year‑old woman on sliding‑scale insulin aspart (NovoLog) with an A1c of 7.2% and high hypoglycemia risk?
Is fecal immunochemical testing (FIT) appropriate for colorectal cancer screening in a bedridden adult aged 50‑75 who cannot reliably provide a stool sample and has limited life expectancy?
What are the differential diagnoses for a 12-year-old with right iliac fossa pain?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.